0:00
Hello everyone.
My name is Nishitha Reddy
and I'm the Associate Professor
of Medicine
at Vanderbilt University Medical Center
and the Director
of the Lymphoma Program here.
Today we'll be discussing
the novel treatment options
that are available for lymphoma
and leukemia treatments.
0:19
So in the last decade, we have seen
an emergence of several new drugs
that have been approved for both Hodgkin
and non-Hodgkin lymphoma,
and most of these agents
are targeted therapies
that were designed
to alter a specific pathway
or antibodies
that bind to a particular site.
As we can see here,
several novel agents have been approved
since 2008 up until now.
Starting in 2008,
bendamustine was approved
for relapsed indolent lymphomas.
And following that,
several new agents have been
approved specifically obinutuzumab,
which is one of the novel
monoclonal antibody therapies
for approval in CLL
and relapsed follicular lymphoma
in combination with bendamustine.
Another agent is brentuximab,
which was approved in 2011
for Hodgkin lymphoma.
And more recently
some of the novel agents
such as PD-1 inhibitors,
specifically nivolumab and pembrolizumab
have been given accelerated approval
for Hodgkin lymphoma.
So in the next several slides,
we will be discussing the mechanisms
of action of these agents,
the current indications,
the side effects of novel agents
used in the treatment of lymphomas
and leukemias.
